4C Medical Group

4C Medical Technologies is a clinical-stage medical device company focused on developing minimally invasive therapies for structural heart disease. The company's flagship technology, the AltaValve, is a transcatheter mitral valve replacement (TMVR) system designed with a unique atrial-only fixation to treat mitral regurgitation while preserving the native mitral annulus and left ventricle. This differentiated approach aims to reduce the risk of complications such as left ventricular outflow tract obstruction, which are common with traditional TMVR devices. 4C Medical is currently advancing the AltaValve through a global pivotal trial and is also developing a transcatheter solution for tricuspid regurgitation. Headquartered in Maple Grove, Minnesota, the company has received significant backing from strategic investors including Boston Scientific and MicroPort CardioFlow.